Current and prospective treatments for multidrug-resistant gram-positive infections

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 14, 2013, Pages 1919-1932

  Rybak, Jeffrey M ^a   Barber, Katie E ^b   Rybak, Michael J ^b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c DETROIT MEDICAL CENTER   (United States)

Author keywords

Combination therapy; Gram positive resistance; HVISA; Investigational agents; MRSA; VISA; VRE

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFEPIME; CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; LEVOFLOXACIN; LINEZOLID; LY 33338; MOXIFLOXACIN; NAFCILLIN; ORITAVANCIN; OXACILLIN; RNA 23S; SOLITHROMYCIN; TEDIZOLID; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIAL LOAD; BACTERIAL MEMBRANE; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BLOODSTREAM INFECTION; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM INFECTION; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; EPSILOMETER TEST; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; INFECTION; INJECTION SITE REACTION; LUNG ALVEOLUS MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOMYELITIS; RECOMMENDED DRUG DOSE; REVIEW; SALVAGE THERAPY; SINGLE DRUG DOSE; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYSTEMIC DISEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84884241161     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.820276     Document Type: Review

References (106)

1. Infectious Diseases Society of America. The 10 20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50(8):1081-3
2. Sievert DMP, Ricks PP, Edwards JR.MS, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1-14
3. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302(21):2323-9
4. Lode H. Management of serious nosocomial bacterial infections: Do current therapeutic options meet the need̈Clin Microbiol Infect 2005;11(10):778-87
5. Santayana EM, Grim SA, Janda WM, et al. Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid. Diagn Microbiol Infect Dis 2012;74(1):39-42
6. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26(2):166-74
7. Werner G, Cuny C, Schmitz FJ, Witte W. Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides. J Clin Microbiol 2001;39(10):3586-90
8. Werner G, Klare I, Spencker FB, Witte W. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. J Antimicrob Chemother 2003;52(1):113-15
9. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346(11):867-9
10. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50(6):821-5
11. Hill CM, Krause KM, Lewis SR, et al. Specificity of induction of the vanA and vanB operons in vancomycin-resistant enterococci by telavancin. Antimicrob Agents Chemother 2010;54(7):2814-18
12. Mendes RE, Tsakris A, Sader HS, et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother 2012;67(6):1321-4
13. Kumon H, Ono N, Iida M, Nickel JC. Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm. Antimicrob Agents Chemother 1995;39(5):1038-44
14. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012;54(6):755-71
15. Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA). Int Med J 2005;35(Suppl2):S136-40
16. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: Epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003;47(10):3040-5
17. Sader HS, Jones RN, Rossi KL, Rybak MJ. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother 2009;64(5):1024-8
18. Pitz AM, Yu F, Hermsen ED, et al. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. J Clin Microbiol 2011;49(1):269-74
19. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46(5):668-74
20. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36(4):429-39
21. Rybak MJ, Leonard SN, Rossi KL, et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46(9):2950-4
22. Sun W, Chen H, Liu Y, et al. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China. Antimicrob Agents Chemother 2009;53(9):3642-9
23. van Hal SJ, Wehrhahn MC, Barbagiannakos T, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011;49(4):1489-94
24. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: Support for consensus guidelines suggested targets. Clin Infect Dis 2011;52(8):975-81
25. Woods CW, Cheng AC, Fowler VG Jr., et al. Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004;38(8):1188-91
26. Moise PA, North D, Steenbergen JN, Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: Facts and assumptions. Lancet Infect Dis 2009;9(10):617-24
27. Cafiso V, Bertuccio T, Spina D, et al. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One 2012;7(1):e29573
28. Jones T, Yeaman MR, Sakoulas G, et al. Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008;52(1):269-78
29. Tauchnitz C, Ezold R, Gonschorek J. The value of fosfomycin. Z Gesamte Inn Med 1982;37(9):253-9
30. Rose WE, Leonard SN, Sakoulas G, et al. daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52(3):831-6
31. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303(22):2260-4
32. Shaw KJ, Barbachyn MR. The oxazolidinones: Past, present, and future. Ann N Y Acad Sci 2011;1241(1):48-70
33. Xiong L, Kloss P, Douthwaite S, et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000;182(19):5325-31
34. Locke JB, Hilgers M, Shaw KJ. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother 2009;53(12):5275-8
35. Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011;365(10):892-900
36. Kamboj MMD, Cohen NP, Gilhuley KBS, et al. Emergence of daptomycin-resistant VRE: Experience of a single institution. Infect Control Hosp Epidemiol 2011;32(4):391-4
37. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: An emerging challenge for clinicians. Clin Infect Dis 2011;52(2):228-34
38. Gomez-Gil R, Romero-Gomez MP, Garcia-Arias A, et al. Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital. Diagn Microbiol Infect Dis 2009;65(2):175-9
39. Dobbs TE, Patel M, Waites KB, et al. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 2006;44(9):3368-70
40. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011;52(3):285-92
41. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
42. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated gram-positive infections: A large, multicenter, retrospective study. Pharmacotherapy 2011;31(6):527-36
43. Hall AD, Steed ME, Arias CA, et al. Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/ pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2012;56(6):3174-80
44. Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: Results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents 2009;33(6):543-8
45. Moise PA, Amodio-Groton M, Rashid M, et al. Clinical outcomes of daptomycin with and without concomitant b-lactams in patients with staphylococcus aureus bacteremia and mild to moderate renal impairment: A multicenter evaluation. Antimicrob Agents Chemother 2012;57(3):1192-200
46. Birmingham MC, Rayner CR, Meagher AK, et al. Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003;36(2):159-68
47. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53(4):646-9
48. Crank CW, Scheetz MH, Brielmaier B, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther 2010;32(10):1713-19
49. Campbell ML, Marchaim D, Pogue JM, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 mug/ml to vancomycin: Old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Ann Pharmacother 2012;46(12):1587-97
50. Balkhair A, Al Muharrmi Z, Darwish L, et al. Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid. Int J Infect Dis 2010;14(Suppl3):e227-9
51. Villegas-Estrada A, Lee M, Hesek D, et al. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: Potent inhibition of PBP 2a by two anti-MRSA b-lactam antibiotics. J Am Chem Soc 2008;130(29):9212-13
52. Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012;67(5):1267-70
53. Lin JC, Aung G, Thomas A, et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: A retrospective case series of 10 patients. J Infect Chemother 2012;19(1):42-9
54. Steed M, Vidaillac C, Rybak MJ. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2011;55(7):3522-6
55. Putnam SD, Sader HS, Moet GJ, et al. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results. Diagn Microbiol Infect Dis 2010;67(4):359-68
56. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012;55(4):582-6
57. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrobial Agents Chemother 2010;54(12):5376-8
58. Hawser SP, Bouchillon SK, Hackel M, et al. Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010. Int J Antimicrob Agents 2012;39(6):490-5
59. Talan DA, Krishnadasan A, Gorwitz RJ, et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011;53(2):144-9
60. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprimsulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005;25(2):253-64
61. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349(17):1628-35
62. Trollfors B, Wahl M, Alestig K. Co-trimoxazole, creatinine and renal function. J Infect 1980;2(3):221-6
63. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009;34(6):506-15
64. Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: A meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010;65(9):1862-77
65. Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008;52(12):4442-7
66. Rodríguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR- 700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67(1):167-9
67. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 2012;56(5):2627-34
68. Sahre M, Sabarinath S, Grant M, et al. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 2012;40(1):51-4
69. Anda CD, Fang E, Green S, et al. Comparison of investigator assessed and programmatic clinical outcomes of tedizolid phosphate vs. linezolid in a phase 3 study in patients with ABSSSI [abstract# L1-1665]. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2012; San Francisco, CA; 2012
70. Putnam SD, Sader HS, Farrell DJ, et al. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: Activity against staphylococci and enterococci. Int J Antimicrob Agents 2011;37(1):39-45
71. Rodvold KA, Gotfried MH, Still JG, et al. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM- 101) in healthy adult subjects. Antimicrob Agents Chemother 2012;56(10):5076-81
72. Oldach D, Clark K, Schranz J, et al. A Randomized, double-blind, multi-center study to evaluate the efficacy and safety of oral solithromycin (CEM- 101) compared to oral levofloxacin in the treatment of patients with community acquired bacterial pneumonia [abstract# P719]. 22nd European Congress of Clinical Microbiology and Infectious Diseases; London, England; 2012
73. Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 2006;58(4):802-5
74. Goldstein BP, Draghi DC, Sheehan DJ, et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007;51(4):1150-4
75. Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: A novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008;46(4):577-83
76. Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 2009;49(4):465-76
77. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41(10):1407-15
78. Goldstein B, Seltzer E, Flamm R, et al. Dalbavancin phase III skin and skin structure (SSSI) studies: Pathogens and microbiological efficacy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2005; Washington, DC; 2005
79. Belley A, McKay GA, Arhin FF, et al. Oritavancin disrupts membrane integrity of staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother 54 (12):5369-71
80. Vidaillac C, Parra-Ruiz J, Rybak MJ. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. Diagn Microbiol Infect Dis 2011;71(4):470-3
81. McKay GA, Beaulieu S, Arhin FF, et al. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 2009;63(6):1191-9
82. Arthur M, Depardieu F, Reynolds P, Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 1999;43(8):1875-80
83. Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin Population Pharmacokinetics in Healthy Subjects and Patients with Complicated Skin and Skin Structure Infections or Bacteremia. Antimicrob Agents Chemother 53 (10):4422-8
84. Mitchell M. SOLO-1 Trial Meets All Protocol-Specified Endpoints; One Single Intravenous Dose of Oritavancin Is Non-Inferior to Twice-Daily Vancomycin Intravenous Dosing for 7-10 Days. 2012. Available from: Http://ir. themedicinescompany.com/phoenix. zhtml?c=122204&p=irolnewsArticle& ID=1768881&highlight [Cited 2 February 2013
85. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179(8):2557-66
86. Leonard SN. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. PloS One 2012;7(7):e42103
87. Hagihara M, Wiskirchen DE, Kuti JL, Nicolau DP. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012;56(1):202-7
88. Climo MW, Patron RL, Archer GL. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob Agents Chemother 1999;43(7):1747-53
89. Fox PM, Lampen RJ, Stumpf KS, et al. Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics. Antimicrob Agents Chemother 2006;50(9):2951-6
90. Werth BJ, Vidaillac C, Murray KP, et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA). Antimicrob Agents Chemother 2013;57(5):2376-9
91. Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 2010;54(8):3161-9
92. Leonard SN, Rolek KM. Evaluation of the combination of daptomycin and nafcillin against vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother 2012;68(3):644-7
93. Werth BJ, Sakoulas G, Rose WE, et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin- nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/ pharmacodynamic model. Antimicrob Agents Chemother 2013;57(1):66-73
94. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004;53(3):530-2
95. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: Role of enhanced daptomycin binding. Clin Infect Dis 2011;53(2):158-63
96. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillinresistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother 2010;54(12):5187-92
97. Steed ME, Werth BJ, Ireland CE, Rybak MJ. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant staphylococcus aureus using an in vitro pharmacokinetic/ pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 2012;56(11):5709-14
98. Miro JM, Entenza JM, Del Rio A, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012;56(8):4511-15
99. Linasmita P. Successful management of methicillin-resistant Staphylococcus aureus bacteremia unresponsive to Vancomycin by adding fosfomycin: A case report. J Med Assoc Thai 2012;95(7):960-3
100. Housman ST, Pope JS, Russomanno J, et al. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 2012;56(5):2627-34
101. Kanafani ZA, Corey GR. Tedizolid (TR-701): A new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 2012;21(4):515-22
102. Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55(7):3453-60
103. Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005;55(Suppl2):ii25-30
104. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007;51(5):1633-42
105. Chen AY, Zervos MJ, Vazquez JA. Dalbavancin: A novel antimicrobial. Int J Clin Pract 2007;61(5):853-63
106. Boylan CJ, Campanale K, Iversen PW, et al. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 2003;47(5):1700-6